| China | España | Turquía | |
| Tomoterapia | de $17,500 | de $35,000 | de $12,000 |
| Terapia intravenosa con resveratrol | de $350 | de $400 | de $200 |
| Terapia intravenosa con curcumina | de $350 | de $450 | de $350 |
| Terapia de protones para el cáncer de mama | de $38,500 | de $85,000 | de $30,000 |
| Terapia con Actinio-225 | de $13,800 | de $45,000 | de $22,955 |
El profesor Shixin Liu, MD, PhD, es el líder de la disciplina del Centro de Oncología. Fue presidente del Hospital Oncológico Provincial de Jilin y director del Instituto de Investigación en Prevención y Tratamiento del Cáncer. Es profesor de nivel II y tutor de doctorado. Ha recibido la Asignación Especial del Gobierno del Consejo de Estado, el 4.º premio Médico Nacional Famoso (Contribución Sobresaliente) y la distinción Modelo de Ética Médica.
Se especializa en el diagnóstico y tratamiento integrales de tumores malignos. Su enfoque es la radioterapia de precisión para cánceres torácicos y abdominales. Domina IMRT, VMAT y SBRT para cáncer de pulmón, esófago, mama y recto.
Sus cargos de liderazgo incluyen la vicepresidencia de Oncología Radioterápica de la CMA, de Radioterapia de la CACA y de Terapia de Partículas de la CACA. Integra el Comité Permanente de la CSCO y es vicepresidente del Comité de Expertos en Oncología Radioterápica de la CSCO. Es vicepresidente de Oncología Radioterápica de la CPAM y miembro del Comité Permanente de la CSMEA. Preside la sección de Oncología Radioterápica de la Asociación Médica de Jilin. Forma parte de los consejos editoriales del Chinese Journal of Radiation Oncology y del Practical Journal of Cancer.
El Dr. Leng Yin se especializa en el tratamiento del cáncer de mama, junto con la oncología de hígado, vesícula biliar y páncreas en el Fuda Cancer Hospital.
El doctor es un experto reconocido en criocirugía mínimamente invasiva para el cáncer, sirviendo como Presidente y cirujano jefe en el Hospital de Cáncer Fuda desde 2001. Con un enfoque en oncología y procedimientos mínimamente invasivos, el doctor ha realizado casi 10,000 criocirugías y 500 procedimientos NanoKnife, tratando a pacientes de entre 4 y 94 años.<\/p>
Graduado de la Cuarta Universidad Médica Militar con especialidad en cirugía torácica y cardíaca, el doctor ha contribuido significativamente al campo con más de 100 artículos publicados. Reconocido con premios por sus contribuciones destacadas a la criocirugía, el doctor ocupa cargos de vicepresidente en las Sociedades Asiática e Internacional de Criocirugía.<\/p>
Escrito por Anna Leonova
China offers high-quality breast cancer treatment in JCI-accredited urban centers. Early-stage survival rates exceed 90% in top-tier facilities. Specialized hospitals in Beijing and Shanghai align with international MDT protocols. Advanced technologies like NanoKnife and CyberKnife M6 provide precise, minimally invasive alternatives for complex cases.
Bookimed Expert Insight: While many seek traditional surgery, China excels in combining immunotherapy with unique ablation techniques. Fuda Cancer Hospital has treated over 30,000 patients from 100 countries using cryosurgery and microwave hyperthermia. This high volume of international cases suggests these specialized protocols are particularly effective for advanced or metastatic breast cancers that require more than standard chemotherapy.
Patient Consensus: Patients note that top-tier urban hospitals provide care rivaling global standards, though they emphasize the need for a translator. Many choose these centers specifically for access to minimally invasive therapies not always available in their home countries.
Advanced breast cancer therapies in China include next-generation antibody-drug conjugates (ADCs) like Trastuzumab Deruxtecan and Sacituzumab Tirumotecan. Patients access innovative targeted therapies, bispecific antibodies, and specialized radiosurgery. Facilities like Fuda Cancer Hospital utilize minimally invasive techniques and cryosurgery for advanced-stage cases.
Bookimed Expert Insight: China has emerged as a primary launch market for global oncology innovations. Some ADCs receive regulatory approval here before other major international bodies. For instance, the Jinshazhou Hospital offers CyberKnife M6 treatments for approximately $7,700 (56,000 CNY). This reflects a trend where high-end technology is bundled with comprehensive logistics like clinic transfers.
Patient Consensus: Patients note that top-tier hospitals provide rapid access to clinical trials for metastatic triple-negative cases. They emphasize the importance of using professional coordinators to navigate language barriers and verify legitimate treatments at state-affiliated centers.
China offers advanced minimally invasive breast cancer treatments including NanoKnife, cryosurgery, and vascular interventional therapy. Specialized centers in Guangzhou utilize these technologies to treat tumors without traditional systemic chemotherapy side effects. These methods target cancer cells while preserving surrounding healthy breast tissue and critical structures.
Bookimed Expert Insight: Data from Fuda Cancer Hospital shows they apply over 10 types of minimally invasive therapies. A key differentiator in China is the high volume of international patients. Fuda alone has treated over 30,000 patients from 100 countries. This suggests a highly standardized protocol for international cases often missing in smaller regional clinics.
Patient Consensus: Patients note that urban centers like Guangzhou provide better access to breast-conserving options. Many emphasize that having a medical advocate is essential for navigating these specialized Chinese oncology treatments.
Major Chinese hospitals provide dedicated support for international patients through specialized International Medical Departments or VIP wings. These units offer bilingual staff, English medical documentation, and streamlined services. Facilities in cities like Guangzhou and Shanghai often hold JCI accreditation to ensure global healthcare standards.
Bookimed Expert Insight: High-volume centers like Fuda Cancer Hospital demonstrate their international focus by treating 30,000 patients from over 100 countries. Data shows that top-tier facilities often employ doctors with extensive global experience. For example, Dr. Leng Yin practiced at major hospitals in Thailand before joining Fuda, ensuring a better understanding of international patient expectations.
Patient Consensus: Patients note that while major cancer centers provide liaison officers and English paperwork, bringing a private interpreter is helpful for complex medical discussions. Many emphasize that using hospital WeChat accounts is the most effective way to coordinate arrival and confirm services beforehand.
Family members are generally allowed to stay with breast cancer patients in China. Most major hospitals permit one designated caregiver to stay overnight in the patient room. Facilities typically provide a folding chair or cot. Access often requires a specific companion card and valid identification like a passport.
Bookimed Expert Insight: While public hospitals offer basic folding chairs for companions, JCI-accredited centers like Fuda Cancer Hospital in Guangzhou manage high international patient volumes with more supportive structures. Our data shows these facilities often accommodate families better because they are used to patients traveling from over 100 countries. If you are choosing between a tier-3 public ward and a specialized center, the latter is more likely to have established protocols for international family support.
Patient Consensus: Patients note it is essential to bring your own bedding and snacks since hospital provisions for caregivers are often very basic. Many emphasize that having a male relative stay in female wards can sometimes face local restrictions, so confirming specific ward rules early is vital.
To obtain a medical visa for breast cancer treatment in China, you must secure an official invitation letter from a Grade 3A hospital. Applicants typically require a short-term S2 visa for stays under 180 days. Complex oncology cases exceeding six months require an S1 visa converted into a medical stay permit.
Bookimed Expert Insight: While many search for general medical visas, targeting JCI-accredited facilities like Fuda Cancer Hospital in Guangzhou can simplify the process. These centers manage high international volumes of over 30,000 patients and have established protocols for issuing the specific invitations required by consulates. This institutional experience often reduces the 4–6 week administrative delays common at smaller, non-accredited hospitals.
Patient Consensus: Patients emphasize that paperwork mismatches are common and suggest translating all medical records early. Many note that getting a guarantee from a top-tier hospital is the only way to avoid visa rejection.
Recommended hospitals for breast cancer in China include Peking Union Medical College Hospital and Fudan University Shanghai Cancer Center. These institutions lead national rankings for multidisciplinary care. Specialized centers like JCI-accredited Fuda Cancer Hospital in Guangzhou offer advanced treatments, including cryosurgery and targeted therapies.
Bookimed Expert Insight: While public giants like Fudan University Shanghai Cancer Center are prestigious, they often have two-month wait times. International patients find better efficiency at JCI-accredited private centers in Guangzhou. These facilities, such as Fuda Cancer Hospital, manage over 30,000 international cases and prioritize rapid treatment starts.
Patient Consensus: Patients note that top public hospitals are very crowded and may have long waits. Many suggest choosing facilities with dedicated international departments to ensure better communication and faster access to specialists.